Efficacy, safety, and tolerability of oral semaglutide versus placebo added to insulin with or without metformin in patients with type 2 diabetes: the PIONEER 8 trial.
Open accessThe DOI matches its Crossref record; 33 of the 37 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To investigate the efficacy, safety, and tolerability of oral semaglutide added to insulin with or without metformin. RESEARCH DESIGN AND METHODS: Patients with type 2 diabetes uncontrolled on insulin with or without metformin were randomized to oral semaglutide 3 mg (N = 184), 7 mg (N = 182), or 14 mg (N = 181) or to placebo (N = 184) in a 52-week, double-blind trial. End points were change from baseline to week 26 in HbA1c (primary) and body weight (confirmatory secondary). Two estimands were defined: treatment policy (effect regardless of trial product discontinuation or rescue medication) and trial product (effect assuming trial product continuation without rescue medication) in randomized patients. RESULTS: Oral semaglutide was superior to placebo in reducing HbA1c (estimated treatment difference [ETD] –0.5% [95% CI –0.7, –0.3], –0.9% [–1.1, –0.7], and –1.2% [–1.4, –1.0] for 3, 7, and 14 mg, respectively; P < 0.001) and body weight (ETD −0.9 kg [95% CI −1.8, −0.0], −2.0 kg [−3.0, −1.0], and −3.3 kg [−4.2, −2.3]; P = 0.0392 for 3 mg, P ≤ 0.0001 for 7 and 14 mg) at week 26 (treatment policy estimand). Significantly greater dose-dependent HbA1c and body weight reductions versus placebo were achieved with oral semaglutide at weeks 26 and 52 (both estimands). The most frequent adverse event with oral semaglutide was nausea (11.4–23.2% of patients vs. 7.1% with placebo; mostly mild to moderate). CONCLUSIONS: Oral semaglutide was superior to placebo in reducing HbA1c and body weight when added to insulin with or without metformin in patients with type 2 diabetes. The safety profile was consistent with other glucagon-like peptide 1 receptor agonists.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In other phase 3 trials, no increase in hypoglycemia risk was observed versus comparator groups, including other GLP-1RAs (18–21, 23, 33–36).”
From Safety of Semaglutide (2021) · cites this paper as [21]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“When added to basal insulin, selective glucagon-like peptide-1 (GLP-1) receptor agonists have demonstrated improved glycemic control and body weight loss without increasing the risk of hypoglycemia and reducing insulin requirements.[2][3][4][5][6]”
From Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes (2022) · cites this paper as [3]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“For oral semaglutide, the placebo-controlled trials found nausea ranged between 5.1 and 23.2% (placebo 5.6–7.1%), vomiting between 2.9 and 9.9% (placebo 2.2–3.8%) and diarrhea between 5.1 and 15% (placebo 2.2–8%) during the on-treatment period (14, 17, 21).”
From Safety of Semaglutide (2021) · cites this paper as [21]
The cited source says what the claim attributes to it.
In the citing paper
“For oral semaglutide, the placebo-controlled trials found nausea ranged between 5.1 and 23.2% (placebo 5.6–7.1%), vomiting between 2.9 and 9.9% (placebo 2.2–3.8%) and diarrhea between 5.1 and 15% (placebo 2.2–8%) during the on-treatment period (14, 17, 21).”
From Safety of Semaglutide (2021) · cites this paper as [21]
The cited source says what the claim attributes to it.
In the citing paper
“For oral semaglutide, the placebo-controlled trials found nausea ranged between 5.1 and 23.2% (placebo 5.6–7.1%), vomiting between 2.9 and 9.9% (placebo 2.2–3.8%) and diarrhea between 5.1 and 15% (placebo 2.2–8%) during the on-treatment period (14, 17, 21).”
From Safety of Semaglutide (2021) · cites this paper as [21]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Statistical Analysis With Missing Data
Lahiff, M., Little, R. J. A., & Rubin, D. B. (1989) · Journal of the American Statistical Association · doi:10.2307/2289883 · Cited by 17,265
Arnett, D. K., Blumenthal, R. S., Albert, M. A., Buroker, A. B., Goldberger, Z. D., Hahn, E. J., Himmelfarb, C. D., Khera, A., Lloyd-Jones, D., McEvoy, J. W., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000678 · Cited by 4,536
(2019) · doi:10.1161/cir.0000000000000677 · Cited by 4,501
Davies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetes Care · doi:10.2337/dci18-0033 · Cited by 3,518
Self-citationStatistical Analysis with Missing Data
Bo., N., Little, R. J. A., & Rubin, D. B. (1988) · Population (French Edition) · doi:10.2307/1533221 · Cited by 2,095
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2019
American Diabetes Association (2019) · Diabetes Care · doi:10.2337/dc19-s009 · Cited by 739
Addition of Biphasic, Prandial, or Basal Insulin to Oral Therapy in Type 2 Diabetes
Holman, R. R., Thorne, K. I., Farmer, A. J., Davies, M. J., Keenan, J. F., Paul, S., & Levy, J. C. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa075392 · Cited by 710
Bethel, M. A., Patel, R. A., Merrill, P., Lokhnygina, Y., Buse, J. B., Mentz, R. J., Pagidipati, N. J., Chan, J. C., Gustavson, S. M., Iqbal, N., et al. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30412-6 · Cited by 599 · cited 1×
“Glucagon-like peptide 1 receptor agonists (GLP-1RAs) reduce HbA1c with a low risk of hypoglycemia and favorable effects on body weight (1,2).”
BackgroundSelf-citationPratley, R., Amod, A., Hoff, S. T., Kadowaki, T., Lingvay, I., Nauck, M., Pedersen, K. B., Saugstrup, T., & Meier, J. J. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31271-1 · Cited by 594
Self-citationStatistical Principles for Clinical Trials
Kay, R. (1998) · Journal of International Medical Research · doi:10.1177/030006059802600201 · Cited by 573
Cited by
GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art
Nauck, M. A., Quast, D. R., Wefers, J., & Meier, J. J. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101102 · Cited by 1,647
Advances in oral peptide therapeutics
Drucker, D. J. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0053-0 · Cited by 646
Dahl, D., Onishi, Y., Norwood, P., Huh, R., Bray, R., Patel, H., & Rodríguez, Á. (2022) · JAMA · doi:10.1001/jama.2022.0078 · Cited by 597
“When added to basal insulin, selective glucagon-like peptide-1 (GLP-1) receptor agonists have demonstrated improved glycemic control and body weight loss without increasing the risk of hypoglycemia and reducing insulin requirements.(2-6)Glucose-dependent insulinotropic polypeptide is the primary incretin hormone respo…”
BackgroundResultSelf-citationSmits, M. M., & Van Raalte, D. H. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.645563 · Cited by 332
Wegovy (Semaglutide): A New Weight Loss Drug for Chronic Weight Management
Singh, G., Krauthamer, M., & Bjalme-Evans, M. (2022) · Journal of Investigative Medicine · doi:10.1136/jim-2021-001952 · Cited by 240
Systemic delivery of peptides by the oral route: Formulation and medicinal chemistry approaches
Brayden, D. J., Hill, T. A., Fairlie, D. P., Maher, S., & Mrsny, R. J. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.05.007 · Cited by 253
Husain, M., Bain, S. C., Jeppesen, O. K., Lingvay, I., Sørrig, R., Treppendahl, M. B., & Vilsbøll, T. (2020) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13955 · Cited by 209
Self-citationMahapatra, M. K., Karuppasamy, M., & Sahoo, B. M. (2022) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-021-09699-1 · Cited by 166
“Dose-dependent decline in HbA1c and body weight was associated with semaglutide than placebo at weeks 26 and 52 for both the treatment policy as well as trial product estimand [74].”
BackgroundClinical Pharmacokinetics of Oral Semaglutide: Analyses of Data from Clinical Pharmacology Trials
Overgaard, R. V., Navarria, A., Ingwersen, S. H., Bækdal, T. A., & Kildemoes, R. J. (2021) · Clinical Pharmacokinetics · doi:10.1007/s40262-021-01025-x · Cited by 170
Gibbons, C., Blundell, J., Tetens Hoff, S., Dahl, K., Bauer, R., & Bækdal, T. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14255 · Cited by 149
A Pharmacological and Clinical Overview of Oral Semaglutide for the Treatment of Type 2 Diabetes
Andersen, A., Knop, F. K., & Vilsbøll, T. (2021) · Drugs · doi:10.1007/s40265-021-01499-w · Cited by 133
Efficacy of semaglutide in a subcutaneous and an oral formulation
Meier, J. J. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.645617 · Cited by 146
Nadolsky, K., Garvey, W. T., Agarwal, M., Bonnecaze, A., Burguera, B., Chaplin, M. D., Griebeler, M. L., Harris, S. R., Schellinger, J. N., Simonetti, J., et al. (2025) · Endocrine Practice · doi:10.1016/j.eprac.2025.07.017 · Cited by 141
Self-citationAroda, V. R., Blonde, L., & Pratley, R. E. (2022) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-022-09735-8 · Cited by 135
“1 Other outcomes of the global phase III trials A greater proportion of patients consistently achieved the ADA-recommended glycemic target (HbA1c < 7%) with oral semaglutide 7 and 14 mg (42–77%) versus placebo (7–31%) and active comparators (25–62%) at the primary analysis time point across the global trials (PIONEER…”
BackgroundMethodSelf-citationThethi, T. K., Pratley, R., & Meier, J. J. (2020) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14054 · Cited by 134
Aroda, V. R., Aberle, J., Bardtrum, L., Christiansen, E., Knop, F. K., Gabery, S., Pedersen, S. D., & Buse, J. B. (2023) · The Lancet · doi:10.1016/s0140-6736(23)01127-3 · Cited by 126
Self-citationGlucagon-Like Peptide 1 Receptor Agonists and Mental Health: A Systematic Review and Meta-Analysis
Pierret, A. C. S., Mizuno, Y., Saunders, P., Lim, E., De Giorgi, R., Howes, O. D., McCutcheon, R. A., McGowan, B., Sen Gupta, P., Smith, D., et al. (2025) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2025.0679 · Cited by 116
Formulation strategies to improve the efficacy of intestinal permeation enhancers,
Maher, S., & Brayden, D. J. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.113925 · Cited by 113
Chiang, C.-H., Jaroenlapnopparat, A., Colak, S. C., Yu, C.-C., Xanthavanij, N., Wang, T.-H., See, X. Y., Lo, S.-W., Ko, A., Chang, Y.-C., et al. (2025) · Gastroenterology · doi:10.1053/j.gastro.2025.06.003 · Cited by 105
Overgaard, R. V., HERTZ, C. L., Ingwersen, S. H., Navarria, A., & Drucker, D. J. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100387 · Cited by 112
Strategies for participant retention in long term clinical trials: A participant –centric approaches
Poongothai, S., Anjana, R. M., Aarthy, R., Unnikrishnan, R., Narayan, K. M. V., Ali, M. K., Karkuzhali, K., & Mohan, V. (2022) · Perspectives in Clinical Research · doi:10.4103/picr.picr_161_21 · Cited by 111
Self-citationTan, Q., Orsso, C. E., Deehan, E. C., Triador, L., Field, C. J., Tun, H. M., Han, J. C., Müller, T. D., & Haqq, A. M. (2019) · Obesity Reviews · doi:10.1111/obr.12992 · Cited by 103
Do GLP-1 Receptor Agonists Increase the Risk of Breast Cancer? A Systematic Review and Meta-analysis
Piccoli, G. F., Mesquita, L. A., Stein, C., Aziz, M. M., Zoldan, M., Degobi, N. A. H., Spiazzi, B. F., Junior, G. L. L., Colpani, V., & Gerchman, F. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa891 · Cited by 99
Magruder, M. L., Miskiewicz, M., Rodriguez, A. N., & Mont, M. A. (2023) · The Journal of Arthroplasty · doi:10.1016/j.arth.2023.12.023 · Cited by 100
Oral semaglutide for type 2 diabetes: A systematic review and meta‐analysis
Avgerinos, I., Michailidis, T., Liakos, A., Karagiannis, T., Matthews, D. R., Τσάπας, Α., & Bekiari, E. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13899 · Cited by 102
Self-citationAllawadhi, P., Singh, V., Govindaraj, K., Khurana, I., Sarode, L. P., Navik, U., Banothu, A. K., Weiskirchen, R., Bharani, K. K., & Khurana, A. (2021) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2021.118923 · Cited by 93
GLP-1 receptor agonists in the treatment of type 2 diabetes: role and clinical experience to date
Brunton, S., & Wysham, C. (2020) · Postgraduate Medicine · doi:10.1080/00325481.2020.1798099 · Cited by 95
Prasad, F., De, R., Korann, V., Chintoh, A. F., Remington, G., Ebdrup, B. H., Siskind, D., Knop, F. K., Vilsbøll, T., Fink-Jensen, A., et al. (2023) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253231165169 · Cited by 88
Self-citationDahl, K., Brooks, A., Almazedi, F., Hoff, S. T., Boschini, C., & Bækdal, T. A. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14373 · Cited by 87
Self-citationSemaglutide and cancer: A systematic review and meta-analysis
Nagendra, L., BG, H., Sharma, M., & Dutta, D. (2023) · Diabetes & Metabolic Syndrome: Clinical Research & Reviews · doi:10.1016/j.dsx.2023.102834 · Cited by 86
Oral semaglutide in type 2 diabetes
Anderson, S. L., Beutel, T. R., & Trujillo, J. M. (2020) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2019.107520 · Cited by 79
Wang, F., Mao, Y., Wang, H., Liu, Y., & Huang, P. (2021) · Clinical Drug Investigation · doi:10.1007/s40261-021-01110-w · Cited by 78
“[35] (PIONEER 8) Semaglutide 3 mg qd 52 184 85.”
A Comprehensive Review on Weight Loss Associated with Anti-Diabetic Medications
Haddad, F., Dokmak, G., Bader, M., & Karaman, R. (2023) · Life · doi:10.3390/life13041012 · Cited by 78
“In PIONEER 8, a 52-week, randomized, double-blind, phase 3 trial, 731 T2DM patients were randomly assigned to receive placebo, 3 mg, 7 mg, or 14 mg of oral semaglutide daily, or to receive either placebo or insulin with or without metformin [195].”
BackgroundMaher, S., Geoghegan, C., & Brayden, D. J. (2020) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2021.1825375 · Cited by 74
Drake, T. C., Landsteiner, A. M. K., Langsetmo, L., MacDonald, R. H., Anthony, M., Kalinowski, C., Ullman, K. E., Billington, C. J., Kaka, A. S., Sultan, S., et al. (2024) · Annals of Internal Medicine · doi:10.7326/m23-1490 · Cited by 74
GLP ‐1 receptor agonists and the risk for cancer: A meta‐analysis of randomized controlled trials
Silverii, G. A., Marinelli, C., Bettarini, C., Del Vescovo, G. G., Monami, M., & Mannucci, E. (2025) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.16489 · Cited by 67
Yoshida, Y., Joshi, P., Barri, S., Wang, J., Corder, A. L., O'Connell, S. S., & Fonseca, V. A. (2022) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2022.108255 · Cited by 65
Aroda, V. R., Erhan, U., Jelnes, P., Meier, J. J., Abildlund, M. T., Pratley, R. E., Vilsbøll, T., & Husain, M. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14990 · Cited by 71
“Blood pressure was modestly decreased in patients treated with subcutaneous/oral semaglutide (systolic: –4/–3; diastolic: –1/–1 mmHg; Table S12).”
BackgroundMethodSelf-citationFeier, C., Vonica, R., Faur, A., Streinu, D., & Muntean, C. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25084346 · Cited by 60
“For instance, studies such as those by Aroda VR et al. [33] and Zinman B et al. [35] were omitted because they did not focus on or mention thyroid cancer incidence, despite discussing semaglutide’s effects in diabetes management.”
BackgroundChao, A. M., Tronieri, J. S., Amaro, A., & Wadden, T. A. (2022) · Drug Design, Development and Therapy · doi:10.2147/dddt.s365416 · Cited by 58
Influence of Bile Composition on Membrane Incorporation of Transient Permeability Enhancers
Hossain, S., Joyce, P. M., Parrow, A., Jõemetsa, S., Höök, F., Larsson, P., & Bergström, C. A. S. (2020) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.0c00668 · Cited by 59
Li, A., Su, X., Hu, S., & Wang, Y. (2023) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.110605 · Cited by 65
Solis‐Herrera, C., Kane, M. P., & Triplitt, C. L. (2023) · Clinical Diabetes · doi:10.2337/cd22-0118 · Cited by 60
Husain, M., Bain, S. C., Holst, A. G., Mark, T., Rasmussen, S., & Lingvay, I. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01106-4 · Cited by 58
Self-citationGranata, A., Maccarrone, R., Anzaldi, M., Leonardi, G., Pesce, F., Amico, F., Gesualdo, L., & Corrao, S. (2022) · Clinical Kidney Journal · doi:10.1093/ckj/sfac069 · Cited by 54
The development of oral semaglutide, an oral GLP-1 analog, for the treatment of type 2 diabetes
Rasmussen, M. F. (2020) · Diabetology International · doi:10.1007/s13340-019-00423-8 · Cited by 57
Xie, X., Yang, S., Deng, S., Liu, Y., Xu, Z., & He, B. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1613610 · Cited by 57
Yeh, T., Tsai, M.-C., Tsai, W.-H., Tu, Y., & Chien, K. (2023) · PLoS ONE · doi:10.1371/journal.pone.0278685 · Cited by 57
Ebrahimi, P., Batlle, J. C., Ayati, A., Maqsood, M. H., Long, C., Tarabanis, C., McGowan, N., Liebers, D. T., Laynor, G., Hosseini, K., et al. (2025) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2025.0091 · Cited by 51
Semaglutide as a GLP-1 Agonist: A Breakthrough in Obesity Treatment
Salvador, R., Moutinho, C. M. S. G., Sousa, C., Vinha, A. F., Carvalho, M. C., & Matos, C. M. (2025) · Pharmaceuticals · doi:10.3390/ph18030399 · Cited by 55
GLP-1/GIP analogs: potential impact in the landscape of obesity pharmacotherapy
Lafferty, R. A., Flatt, P. R., & Irwin, N. (2023) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2023.2192865 · Cited by 54
“reductions and tolerability in the PIONEER 8 trials in T2DM patients [43].”
BackgroundBanerjee, M., Pal, R., Mukhopadhyay, S., & Nair, K. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad076 · Cited by 52
Peptidyl and Non-Peptidyl Oral Glucagon-Like Peptide-1 Receptor Agonists
Choe, H. J., & Cho, Y. M. (2021) · Endocrinology and Metabolism · doi:10.3803/enm.2021.102 · Cited by 50
“A series of 10 phase 3 multicenter, randomized clinical studies as part of the Peptide InnOvatioN for Early diabetes tReatment (PIONEER) program were conducted to compare the efficacy and safety of oral semaglutide with either placebo or active comparators [21-31].”
BackgroundKo, A., Chang, Y.-C., Bahar, F., Wang, T. H., Xanthavanij, N., Yu, C.-C., Hsieh, R. J.-L., See, X. Y., Lo, S., Song, J., et al. (2025) · Annals of Internal Medicine · doi:10.7326/annals-25-02237 · Cited by 56
Long-acting GLP-1RAs: An overview of efficacy, safety, and their role in type 2 diabetes management
Chun, J. H., & Butts, A. (2020) · JAAPA · doi:10.1097/01.jaa.0000669456.13763.bd · Cited by 45
Real-world effectiveness of adding newer generation GLP-1RA to SGLT2i in type 2 diabetes
Chaiyakunapruk, N., Tan, X., Liang, Y. M., Guevarra, M., Xie, L., & CHENG, A. Y. Y. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02737-1 · Cited by 47
Yin, D., Ding, L., Zhou, H., Qiu, M., & Duan, X.-Y. (2021) · Endocrine Journal · doi:10.1507/endocrj.ej21-0129 · Cited by 44
Xia, L., Shen, T., Dong, W., Su, F., Wang, J., Wang, Q., Niu, S., & Fang, Y. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.108904 · Cited by 40
Aroda, V. R., Bauer, R., Christiansen, E., Haluzík, M., Kallenbach, K., Montanya, E., Rosenstock, J., & Meier, J. J. (2022) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14710 · Cited by 38
“The efficacy and safety of oral semaglutide have been established in patients with T2D in the global phase 3a PIONEER programme.(11-18) To provide physicians with data to support the decision-making process and to better understand what responses they might expect with oral semaglutide in different patient groups, a c…”
BackgroundMethodSelf-citationZaazouee, M. S., Hamdallah, A., Helmy, S. K., Hasabo, E. A., Sayed, A. K., Gbreel, M. I., Elmegeed, A. A., Aladwan, H., Elshanbary, A. A., Abdel‐Aziz, W., et al. (2022) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2022.102511 · Cited by 45
Ocular Adverse Events With Semaglutide: A Systematic Review and Meta-Analysis
Natividade, G. R., Spiazzi, B. F., Baumgarten, M. W., Bassotto, C., Pereira, A. A., Fraga, B. L., Scalco, B. G., Mattes, N. R., Lavinsky, D., Kramer, C. K., et al. (2025) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2025.2489 · Cited by 41
Li, J., He, K., Ge, J., Li, C., & Jing, Z. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.108656 · Cited by 45
Chubb, B., Gupta, P., Gupta, J., Nuhoho, S., Kallenbach, K., & Orme, M. E. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01034-w · Cited by 41
Kim, H. S., & Jung, C. H. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22189936 · Cited by 45
“Patients were given a 20% lower insulin dose before starting the study drug, which they continued for 8 weeks until an increase was required [44].”
BackgroundMethodInfluentialAlhindi, Y. A., & Avery, A. (2022) · Contemporary Clinical Trials Communications · doi:10.1016/j.conctc.2022.100944 · Cited by 42
Hosseinpour, A., Sood, A., Kamalpour, J., Zandi, E., Pakmehr, S., Hosseinpour, H., Sood, A., Agrawal, A., & Gupta, R. (2024) · Clinical Cardiology · doi:10.1002/clc.24314 · Cited by 40
“Quality appraisal of the included trials showed an overall low risk of bias for 16 trials [3, 8, 16, 17, 19 – 22, 25, 29 – 35] and six trials [14, 18, 24, 26 – 28] were rated as having some concerns.”
Oral Delivery of Biologics via the Intestine
New, R. R. C. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics13010018 · Cited by 42
“In the case of semaglutide, tested by Novo Nordisk [65], and containing SNAC as absorption-enhancing agent, an additional uptake mechanism has been proposed, implicating transcellular uptake in the stomach, brought about by changing the pH or the local microenvironment [66].”
BackgroundOral GLP-1 analogue: perspectives and impact on atherosclerosis in type 2 diabetic patients
Saraiva, J. F. K., & Franco, D. R. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01417-0 · Cited by 41
“Compared with active drugs, oral semaglutide was superior to empagliflozin in reducing total cholesterol and LDL [36] and was superior to sitagliptin in reducing total cholesterol, LDL, Ta bl e 1 G LP -1 re ce pt or a go ni st s: ca rd io va sc ul ar in di ca tio ns a nd C VO Ts re su lts CV c ar di ov as cu la r, CV…”
BackgroundInfluentialBuse, J. B., Bode, B. W., Mertens, A., Cho, Y. M., Christiansen, E., Hertz, C. L., Nielsen, M. A., & Pieber, T. R. (2020) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2020-001649 · Cited by 38
Self-citationWang, W., Bain, S. C., Bian, F., Chen, R., Gabery, S., Huang, S., Jensen, T. B., Luo, B., Yuan, G., Ning, G., et al. (2024) · Diabetologia · doi:10.1007/s00125-024-06142-3 · Cited by 42
Wright, E. E., & Aroda, V. R. (2020) · Postgraduate Medicine · doi:10.1080/00325481.2020.1798127 · Cited by 47
Self-citationKick, A., M'Rabet‐Bensalah, K., Acquistapace, F., Amadid, H., Ambühl, R. A., Braae, U. C., Item, F., Schultes, B., Züger, T., & Rudofsky, G. (2024) · Diabetes Therapy · doi:10.1007/s13300-023-01525-y · Cited by 41
A Review on the Efficacy and Safety of Oral Semaglutide
Niman, S., Hardy, J., Goldfaden, R. F., Reid, J., Sheikh‐Ali, M., SUTTON, D. R., & Choksi, R. R. (2021) · Drugs in R&D · doi:10.1007/s40268-021-00341-8 · Cited by 43
Hauge, C., Breitschaft, A., Hartoft‐Nielsen, M., Jensen, S., & Bækdal, T. A. (2021) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2021.1955856 · Cited by 41
Arredouani, A. (2025) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2025.108824 · Cited by 36
Ngabea, M. A., & Dimeji, I. Y. (2025) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2025.152822 · Cited by 35
Anam, M., Maharjan, S., Amjad, Z., Abaza, A., Vasavada, A. M., Sadhu, A., Valencia, C., Fatima, H., & Nwankwo, I. (2022) · Cureus · doi:10.7759/cureus.32610 · Cited by 35
“No clinically relevant changes in blood pressure or other safety laboratory assessments were noticed [13, 19-21].”
BackgroundResultInfluentialAdvances in GLP-1 treatment: focus on oral semaglutide
Eliaschewitz, F. G., & Canani, L. H. (2021) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-021-00713-9 · Cited by 34
“Additionally, at baseline, the overall mean total daily insulin dosage was 58 units [46].”
BackgroundInfluentialChronic kidney disease as a cardiovascular risk factor
Carmena, R., Ascaso, J. F., & Redón, J. (2020) · Journal of Hypertension · doi:10.1097/hjh.0000000000002506 · Cited by 39
Wan, J., Ferrari, C., & Tadros, M. S. (2024) · Gastroenterology Insights · doi:10.3390/gastroent15010014 · Cited by 34
“For oral semaglutide, the occurrence rates were 5.1 to 23.2% for nausea, 2.9 to 9.9% for vomiting, and 5.1 to 15% for diarrhea during the on-treatment period [54–56].”
BackgroundInfluentialGlucagon-Like Peptide 1 Receptor Agonists – Potential Game Changers in the Treatment of Glaucoma?
Mouhammad, Z. A., Vohra, R., Horwitz, A., Thein, A., Andreasen, J. R., Cvenkel, B., Williams, P. A., Azuara‐Blanco, A., & Kolko, M. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.824054 · Cited by 35
Ding, Y., Shi, Y., Guan, R., Yan, S., Liu, H., Wang, Z., Li, J., Wang, T., Cai, W., & Ma, G. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2023.107031 · Cited by 31
Allocca, S., Monda, A., Messina, A., Casillo, M., Sapuppo, W., Monda, V., Polito, R., Maio, G. D., Monda, M., & Marra, M. L. (2025) · Healthcare · doi:10.3390/healthcare13121437 · Cited by 37
Glucagon-like peptide-1 receptor agonists in neurodegenerative diseases: Promises and challenges
Zhou, Z., Yi, L., Popławska-Domaszewicz, K., Chaudhuri, К. R., Jankovic, J. J., & Tan, E. K. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.107770 · Cited by 35
Jain, A., Reichert, S. M., Amadid, H., Braae, U. C., Bradley, R. M., Kim, J. W., Soo, V., & Yale, J. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15493 · Cited by 31
“14,16,17 The reduction in BW (7.19 kg at EoS) was generally greater in the current study when compared with the Phase 3 PIONEER trials that continued for a similar duration (approximate reductions of 2.6-4.3 kg after 52 weeks in PIONEER 2, 3, 4, 7 and 8 for oral semaglutide 14 mg or flexibly dosed…”
ResultInfluentialManagement of type 2 diabetes with oral semaglutide: Practical guidance for pharmacists
Kane, M. P., Triplitt, C. L., & Solis‐Herrera, C. (2020) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxaa413 · Cited by 41
Candido, R., Gaiotti, S., Giudici, F., Toffoli, B., Luca, F. D., Velardi, V., Petrucco, A., Gottardi, C., Manca, E., Buda, I., et al. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12186052 · Cited by 29
Wu, W., Tong, H.-M., Li, Y., & Cui, J. (2023) · Endocrine · doi:10.1007/s12020-023-03636-9 · Cited by 30
Małyszczak, A., Przeździecka-Dołyk, J., Szydełko-Paśko, U., & Misiuk‐Hojło, M. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13061797 · Cited by 30
Jordy, A. B., Albayaty, M., Breitschaft, A., Anderson, T. W., Christiansen, E., Houshmand‐Oeregaard, A. S., Manigandan, E., & Bækdal, T. A. (2021) · Clinical Pharmacokinetics · doi:10.1007/s40262-020-00976-x · Cited by 31
Yamada, H., Yoshida, M., Funazaki, S., Morimoto, J., Tonezawa, S., Takahashi, A., Nagashima, S., Masahiko, K., Kiyoshi, O., & Hara, K. (2023) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd10040176 · Cited by 29
“However, PIONEER 8 was performed in patients with a longer average disease duration (about 15 years), but oral semaglutide was shown to be effective [28].”
BackgroundSemaglutide: a key medication for managing cardiovascular-kidney-metabolic syndrome
MacIsaac, R. J. (2025) · Future Cardiology · doi:10.1080/14796678.2025.2511412 · Cited by 30
“Similarly, the PIONEER (Peptide Innovation for Early Diabetes Treatment) program focused on the oral formulation of semaglutide (at doses of 3, 7 and 14 mg OD), which also outperformed placebo and active comparators, such as a DPP-4i and SGLT2i, in terms of glycemic control [5,9,73– 80].”
InfluentialMarassi, M., & Fadini, G. P. (2024) · Clinical Therapeutics · doi:10.1016/j.clinthera.2024.11.005 · Cited by 27
Ji, L., Agesen, R. M., Bain, S. C., Fu, F., Gabery, S., Geng, J., Li, Y., Lu, Y., Luo, B., Pang, W., et al. (2024) · Diabetologia · doi:10.1007/s00125-024-06133-4 · Cited by 27
“Although Asian racial and ethnic groups were included in the PIONEER trials [12–19], and the efficacy and safety of oral semaglutide in a predominantly Japanese population were demonstrated during PIONEER 9 and 10 [20, 21], there is limited evidence available for oral semaglutide from a…”
InfluentialEffects of GLP-1 Agonists on mortality and arrhythmias in patients with Type II diabetes
Al‐Sadawi, M., Aslam, F. M., Tao, M., Alsaiqali, M., Almasry, I. O., Fan, R., Rashba, E. J., & Singh, A. (2023) · IJC Heart & Vasculature · doi:10.1016/j.ijcha.2023.101218 · Cited by 34
Liu, Y., He, L., Han, S., Ping, F., Li, W., Xu, L., Zhang, H., & Li, Y. (2025) · Journal of the American Heart Association · doi:10.1161/jaha.124.039446 · Cited by 27
Mechanism of Semaglutide in MASLD Treatment: Where Is the Master Key?
Ezhilarasan, D. (2025) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.17037 · Cited by 28
Optimizing Therapeutic Outcomes With Oral Semaglutide: A Patient-Centered Approach
Isaacs, D. M., Kruger, D. F., & Spollett, G. R. (2020) · Diabetes Spectrum · doi:10.2337/ds20-0016 · Cited by 26
“Body weight reductions were significantly greater with oral semaglutide versus placebo (oral semaglutide 3, 7, and 14 mg) (59,61,64), sitagliptin 100 mg (oral semaglutide 3, 7, and 14 mg at 26 weeks in PIONEER 3; flexible dose adjustment of oral semaglutide in PIONEER 7) (60,63), and liraglutide 1.”
BackgroundIntegrating oral semaglutide into clinical practice in primary care: for whom, when, and how?
Brunton, S., Mosenzon, O., & Wright, E. E. (2020) · Postgraduate Medicine · doi:10.1080/00325481.2020.1798162 · Cited by 29
Glucagon-like peptide 1-receptor agonists and A1c: Good for the heart but less so for the eyes?
Albert, S. G., Wood, E. M., & Ahir, V. (2022) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2022.102696 · Cited by 26
Metadata
- Authors
- Zinman, B., Aroda, V. R., Buse, J. B., Cariou, B., Harris, S. B., Hoff, S. T., Pedersen, K. B., Tarp-Johansen, M. J., Araki, E., PIONEER 8 Investigators, Zinman, B., Fikry, S., Bajaj, H., Landry, D., Caplan, D., Woo, V., Harris, S., Thuan, J.-F., Serusclat, P., Cariou, B., Gourdy, P., Fradet, G., Monier, A., Borot, S., Monguillon, P., Gouet, D., Doupis, J., Tentolouris, N., Tsimichodimos, V., Melidonis, A., Bekiari, E., Bargiota, A., Agarwal, S., Saboo, B., Chatterjee, S., Mohan, V., Shaikh, S., Gupta, Y., Bhattacharyya, A., Manikath, N., Jain, S., Sasaki, T., Osonoi, T., Fukuda, S., Wada, S., Kiyosue, A., Ide, Y., Onishi, Y., Matoba, K., Takai, K., Yamauchi, A., Inoue, S., Kaneko, S., Ikeda, H., Ohta, Y., Hisatomi, A., Senokuchi, T., Jinnouchi, H., Nakamura, S., Soto, J. R. L., Briones, I. R., Bogdanski, P., Szyprowska, E., Modzelewska, A., Wozniak, I., Zyangirova, S., Sergeeva-Kondrachenko, M., Davis, T., Thomson, S., Frias, J., Gandy, W., Lingvay, I., Pounds, K., Bowman-Stroud, C., Dempsey, M., Huffman, D., Ahmed, A., Fraser, N., Ortiz-Carrasquillo, R., Bolster, D. E., Adams, M., Hummel, M., Free, A., Houser, P., Shockey, G., Barnum, O., Bhasker, K., Cornett, G., Streja, D., Kirby, W., Lynd, S., Folkerth, S., Nakhle, S., Norwood, P., Perez, R., Snyder, B., Farris, N., Litchfield, W., Hamdy, O., Park, J., Aroda, V., & Buse, J.
- Affiliations
- Division of Endocrinology, Diabetes, and Hypertension, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA
- University of North Carolina at Chapel Hill (US)
- Department of Family Medicine, Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada
- Novo Nordisk A/S, Søborg, Denmark
- Novo Nordisk (Denmark) (DK)
- Kumamoto University (JP)
- ORCID
- Aroda, Vanita R.
- Buse, John B.
- Harris, Stewart B.
- Araki, Eiichi
- Bajaj, Harpreet
- Woo, Vincent
- Gourdy, Pierre
- Borot, Sophie
- Bekiari, Eleni
- Saboo, Banshi
- Chatterjee, Sanjay
- Mohan, Viswanathan
- Shaikh, Shehla
- Gupta, Yashdeep
- Bhattacharyya, Arpandev
- Sasaki, Takashi
- Osonoi, Takeshi
- Kiyosue, Arihiro
- Onishi, Yukiko
- Kaneko, Shizuka
- Ikeda, Hiroki
- Ohta, Yasuharu
- Senokuchi, Takafumi
- Jinnouchi, Hideaki
- Nakamura, Shuji
- Lingvay, Ildiko
- Norwood, Paul
- Hamdy, Osama
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2019-07-10
- Volume
- 42
- Issue
- 12
- Pages
- 2262-2271
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC7364672
- OpenAlex
- W2974714926
- Semantic Scholar
- dfcdee292cee0de5fee471e8d85a78bf385a1d29
- Cited by
- 300
- References
- 37
- Citations by year
- 2026: 28 · 2025: 62 · 2024: 51 · 2023: 32 · 2022: 39 · 2021: 43 · 2020: 41 · 2019: 3
- FWCI
- 25.55
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Diabetes Care (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion)
- UNC Libraries
- Funders
- American Diabetes Association
- Amgen
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- Sanofi
- CSL Behring
- Regeneron Pharmaceuticals
- Les Laboratories Pierre Fabre
- MannKind Corporation
- Kowa Company
- Zafgen
- Boehringer Ingelheim Japan
- Eisai
- Novo Nordisk (U54-DK-118612, UC4-DK-108612, UL1-TR-002489)
- Astellas Pharma
- Shionogi
- Terumo
- Mitsubishi Tanabe Pharma Corporation
- Ono Pharmaceutical
- National Institutes of Health (UL1TR002489, UL1-TR-)
- Japan Society for the Promotion of Science (17H04201, 18K08482)
- National Institute of Diabetes and Digestive and Kidney Diseases (UC4DK108612, U01DK098246, U54DK118612)
- National Center for Advancing Translational Sciences
- Daiichi Sankyo Europe
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Keywords
- oral semaglutide, type 2 diabetes, insulin, metformin, glycemic control, HbA1c, weight loss, nausea, GLP-1 receptor agonists, treatment policy estimand, dose-dependent effects, uncontrolled diabetes, adverse events, tolerability, rescue medication, treatment discontinuation
- MeSH terms
- Semaglutide, Adult, Body Weight, Diabetes Mellitus, Type 2, Double-Blind Method, Drug Therapy, Combination, Glucagon-Like Peptides, Female, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Insulin, Male, Metformin, Middle Aged, Nausea, Weight Loss, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.